These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11229847)

  • 21. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
    Chmiel C; Speich R; Hofer M; Michel D; Mertens T; Weder W; Boehler A
    Clin Infect Dis; 2008 Mar; 46(6):831-9. PubMed ID: 18269330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
    Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
    Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.
    Luan FL; Kommareddi M; Ojo AO
    Transplantation; 2011 Jan; 91(2):237-44. PubMed ID: 21169881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
    Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
    J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.
    Díaz-Pedroche C; Lumbreras C; Del Valle P; San Juan R; Hernando S; Folgueira D; Andrés A; Delgado J; Meneu JC; Morales JM; Moreno E; Aguado JM
    Transplant Proc; 2005 Nov; 37(9):3766-7. PubMed ID: 16386532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS.
    Kempen JH; Frick KD; Jabs DA
    Pharmacoeconomics; 2001; 19(12):1199-208. PubMed ID: 11772155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
    J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation.
    Ko GB; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Kim YH; Park JB; Lee SK; Park SK; Park JS; Han DJ; Lee SO
    Transpl Infect Dis; 2013 Aug; 15(4):416-23. PubMed ID: 23676124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
    Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation.
    Dmitrienko S; Yu A; Balshaw R; Shapiro RJ; Keown PA;
    Kidney Int; 2007 Oct; 72(8):1014-22. PubMed ID: 17700642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R
    Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
    Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
    Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ganciclovir prophylaxis for CMV disease infrequently associated with viral resistance.
    AIDS Patient Care; 1995 Dec; 9(6):308. PubMed ID: 11361450
    [No Abstract]   [Full Text] [Related]  

  • 39. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
    Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
    Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.